Apalutamide
from OncoPharm Hosted by John Bossaer
Apalutamide's FDA-approval is discussed, including discussion of its drug interaction potential and a review of the SPARTAN study. Updates (18:15) from ASCO GU and DOAC use in cancer (23:50) also discussed.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 28 minutes long.
When was this OncoPharm episode published?
This episode was published on February 15, 2018.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.